Clinical trials
Brain Tumor, Recurrent clinical trials
Below are recruiting brain tumor, recurrent clinical trials, each written for real people, not researchers. We’re tracking 132 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07492316RecruitingPhase 1
RNA vaccine study for recurrent medulloblastoma
This trial tests a personalized RNA vaccine for children and young adults whose medulloblastoma has come back. The vaccine is made from your own tumor material and aims to help your immune system fight the cancer.
Gainesville, FloridaAges 4–39 - NCT05701306RecruitingPhase 1
Testing a new medicine for hard-to-treat childhood tumors
This Phase 1 trial tests APG-115 alone or with another drug (APG-2575) in children whose neuroblastoma or other solid tumors have come back or did not respond to treatment. It aims to find a safe dose and see how well the treatment works in these tumors.
Guangzhou, GuangdongAges 12–18 - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT02639325Recruiting
Seizure treatment study for people with brain tumors
This study looks at how a brain tumor-related seizure condition is handled in children and adults. It may be a good option if your seizures started soon after your brain tumor was found or is in the same brain area as your seizure symptoms.
Bethesda, MarylandAges 8–99 - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT06471673RecruitingPhase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Santa Monica, CaliforniaAges 18 years+ - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT04501705Recruiting
Apatinib for adults with recurring atypical or malignant meningioma
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
Beijing, Beijing MunicipalityAges 18–70 - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT05859334RecruitingPhase 2
Erdafitinib for brain tumors that came back or worsened
This Phase 2 study tests erdafitinib, a targeted anti-cancer medicine, for certain brain cancers that have returned or progressed after standard treatment. It may help if your tumor has a specific genetic change (FGFR-TACC fusion) that this drug is designed to attack.
Aurora, ColoradoAges 18 years+ - NCT06815432RecruitingPhase 1
CAR T cells for recurrent glioblastoma that makes GPC3
This trial tests a treatment made from your own immune cells, called CAR T cells, which are engineered to find and attack brain tumor cells that have a marker called GPC3. It is for patients whose glioblastoma has come back and who are already scheduled to have another surgery to remove the tumor.
Houston, TexasAges 21–70 - NCT07506239Recruiting
Laser therapy for low-grade brain tumors in young people
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
San Francisco, CaliforniaAges 2–25 - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT07464925RecruitingPhase 1
Testing GLIX1 for adults with returning high-grade glioma
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
Tampa, FloridaAges 18 years+ - NCT04501718RecruitingPhase 2
Study of apatinib plus chemotherapy for recurrent childhood medulloblastoma
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
BeijingAges 2–21 - NCT05259605Recruiting
Study uses brain tumor tissue and scans to track treatment outcomes
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
InnsbruckAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06082648Recruiting
Brain and bowel recovery after ultra-low rectal cancer surgery
This trial studies how a noninvasive brain stimulation technique (TMS) and brain scans (fMRI) might help improve bowel function and quality of life after surgery for ultra-low rectal tumors. It is for patients who have had a specific surgery (intersphincteric resection) and a temporary ileostomy.
ShanghaiAges 18–75 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75
Hear when a new Brain Tumor, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain tumor, recurrent?
- Yes. Clin2 currently lists 132 recruiting brain tumor, recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain tumor, recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain tumor, recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.